This article is more than 5 years old. Information may no longer be current.
Promising 8-year results seen with reverse shoulder arthroplasty prosthesis
Click Here to Manage Email Alerts
Recently published results showed a survival rate of 97.4% at 8 years with a specific reverse shoulder arthroplasty prosthesis.
“In case of primary reversed shoulder arthroplasty, long-term results show a high survival rate of more than 95%,” Alexander Van Tongel, MD, PhD, and Lieven De Wilde MD, PhD, told Healio.com/Orthopedics.
Researchers identified 126 primary Delta Xtend prostheses (DePuy Synthes) implanted between October 2006 and December 2009. There was a follow-up of at least 8 years available for 74 patients. The mean follow-up was 113.1 months. Shoulder function and pain were evaluated with age- and sex-adjusted Constant-Murley scores.
Results showed the mean age- and sex-adjusted Constant-Murley score was 44.6% preoperatively and was 75.8% at 3 months postoperatively and was 91.1% at 5 years. The mean age- and sex-adjusted Constant-Murley score at the latest follow-up visit was 79.9%. This was significantly lower compared with the age- and sex-adjusted Constant-Murley score at 5 years postoperatively. At the 8-year follow-up, the overall survival rate was 97.4%. – by Monica Jaramillo
Perspective
Back to Top
Peter N. Chalmers, MD
The expanding utilization of reverse total shoulder arthroplasty (RTSA) has raised concerns about potential unknown long-term consequences. While several studies have provided long-term results for small groups of patients (<25 patients) to date, the only large series with long-term follow-up was from Dr. Walch’s group.
Bassens and colleagues have published less than 8-year follow-up on 74 patients who underwent RTSA using the Delta Xtend implant, with a follow-up rate of 84% after the exclusion of deceased patients. The authors present no revisions or implant failures beyond the early post-operative period, with an impressive 97.4% implant retention rate. However, the authors do report a decline in constant scores between 5 years and final follow-up related to a loss of abduction strength and range of motion without a change in pain. This decline mirrors that previously published by Dr. Walch. While the source of this functional decline is unclear, this study confirms this decline and identifies long-term deltoid dysfunction as a target for improvement in the future of RTSA.
References:
Bacle G, et al. J Bone Joint Surg Am. 2017; doi:10.2106/JBJS.16.00223.
Bassens D, et al. J Shoulder Elbow Surg. 2019;doi:10.1016/j.jse.2018.11.043.
Chalmers PN, et al. Curr Rev Musculoskelet Medicine. 2016;doi:10.1007/s12178-016-9316-0.
Chalmers PN, et al. J Am Acad Orthop Sur. 2018;doi:10.5435/JAAOS-D-17-00075.
Ernstbrunner L, et al. J Bone Joint Surg Am. 2017;doi:10.2106/JBJS.17.00095.
Gerber C, et al. J Shoulder Elbow Surg. 2018;doi:10.1016/j.jse.2017.10.037.
Department of orthopedic surgery
Salt Lake City
Read more about
Click Here to Manage Email Alerts